The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Arqule’s investors have done pretty nicely out of today’s buyout by Merck & Co, but might be wondering whether they could have done better still.
Biolinerx’s BL-8040 needs to show improved responses in pancreatic cancer while investors will get a first look at Homology's HMI-102, a gene therapy for…
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.